Por: Fox Business Business December 30, 2022
Check out what's clicking on FoxBusiness.com A report by two House committees questioned the approval process for an Alzheimer’s drug produced by Biogen. Congressional investigators called the process rife with irregularities.The drug in question is Aduhelm, which was approved for use in 2021 even though research studies failed to prove it really helped patients. The 18-month investigation detailed atypical collaboration between FDA... + full article
Fox Business USA Business December 30, 2022
BioVie president and CEO Cuong Do discusses the positive results of its Parkinson's and Alzheimer's phase 2 trials and explains how its NE3107 drug could reverse the biological clock on 'Varney & Co.' An 18-month-long investigation conducted by the House... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
Probe: Alzheimer's drug approval 'rife with irregularities' | 10 WBNS
The Boston Globe USA Business December 03, 2022
Michael Bawduniak’s heart was racing when the Biogen marketing manager met with his boss at the drug firm’s headquarters in Weston.His relationship with Tony Kingsley, he says, had soured after Bawduniak balked at what he describes as an increasingly brazen scheme to give... + más
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
Biogen to pay $900m to settle whistle-blower suit over kickbacks | The Boston Globe
ABC News USA Health November 11, 2022
Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm. The company said Thursday that the 62-year-old Viehbacher will become president and CEO... + más
Biogen tabs veteran pharma leader Viehbacher as next CEO | Associated Press
Associated Press USA Health November 11, 2022
Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the . The company said Thursday that the 62-year-old Viehbacher will become president and CEO on Monday, replacing Michel... + más
Biogen tabs veteran pharma leader Viehbacher as next CEO | ABC News
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
Fox Business USA Business September 27, 2022
Aflac Chairman and CEO Dan Amos says record-high inflation poses a ‘challenging environment’ for consumers. Biogen has to settle allegations that it paid kickbacks to persuade doctors to prescribe its multiple sclerosis drugs. The settlement comes after former Biogen... + más
CNBC USA Health September 27, 2022
In this articleA Biogen facility in Cambridge, Massachusetts.Brian Snyder Reuters will pay $900 million to settle a lawsuit that alleged the company gave doctors kickbacks to encourage them prescribe its drugs, the Justice Department announced on Monday.A former Biogen employee... + más
About iurex | Privacy Policy | Disclaimer |